Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.

Name: Kaimen Rigor review — Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.
Item: Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.
Rating: 100
Author: Alpha1

De Laere B, Crippa A, Discacciati A, Larsson B, Persson M, Johansson S, D'hondt S, Bergström R, Chellappa V, Mayrhofer M, Banijamali M, Kotsalaynen A, Schelstraete C, Vanwelkenhuyzen JP, Hjälm-Eriksson M, Pettersson L, Ullén A, Lumen N, Enblad G, Thellenberg Karlsson C, Jänes E, Sandzén J, Schatteman P, Nyre Vigmostad M, Olsson M, Ghysel C, Sautois B, De Roock W, Van Bruwaene S, Anden M, Verbiene I, De Maeseneer D, Everaert E, Darras J, Aksnessether BY, Luyten D, Strijbos M, Mortezavi A, Oldenburg J, Ost P, Eklund M, Grönberg H, Lindberg J

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 3★ (Adequate), 0 critical, 3 high issues for “Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Read alongside

Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.

Read full text (PMC)

DOI

10.1038/s41591-024-03204-2

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/4d627ac3-2234-4f07-8f7e-5ca9b6148f7f" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/4d627ac3-2234-4f07-8f7e-5ca9b6148f7f/badge" alt="Kaimen Rigor review — 3★ (Adequate), 0 critical, 3 high issues for “Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

119b0cdd1eb1faaf6a732f1d055e849abac2ab47e6cec9e5b3ab711449bddee4

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.

Paper source

Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

CitationsCitations & links (capped) ×8−1★
IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★

Citations & links are capped at −1★ combined, however many are flagged.

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No reported statistical tests were found to recompute.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is time to no longer clinically benefitting (NLCB), a composite of PSA, radiologic, and clinical progression, which is a surrogate for overall survival. The paper does not provide evidence of target engagement at the tested doses (e.g., PK/PD) nor does it cite validated evidence linking NLCB to overall survival in this setting. Although overall survival is reported as a secondary endpoint, the primary efficacy claim is based on NLCB.
“The primary endpoint was the time to no longer clinically benefitting (NLCB).”
Find in source
02Other integrity concern
mediumAuthenticityreviewer-assessedFull detail
Trial NCT03903835 was first submitted to ClinicalTrials.gov on 2019-03-29, after the registered study start date of 2019-02-01. Retrospective registration means the protocol and outcomes were not on the public record before the study ran, which is what prospective registration exists to establish.
NCT03903835
reviewer’s wording

Findings by category

01ArithmeticNone found 202OverreachOverstated conclusions 103AuthenticityData authenticity concerns 04DisclosureNone found 105AvailabilityBroken references and links 06Copyedit5 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper is a well-conducted, biomarker-driven adaptive platform trial with strong methodological rigor, clear reporting of ethics, data/code availability, and statistical methods. Minor gaps include lack of explicit reporting guideline, missing race/ethnicity data, and unverified model assumptions, but these do not undermine the overall validity.

Both reviewers classified the study as interventional; no divergence. The evaluation covered the full text, with N/A for animal-related and bench-resource criteria. The statistics verification component found no recomputable tests, so statistical correctness is not claimed beyond what was reported. The integrity check flagged retrospective registration (submitted after study start), which is a transparency concern but not a validity threat.

Numerical inconsistencies

None found

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Checked — nothing surfaced.

Overstated conclusions

2 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Conclusions only partially backed by the presented evidenceAssessed

8 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Data authenticity concerns

1 finding · worst medium

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

1 integrity concern flagged (0 high).

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

The introduction cites prior retrospective analyses suggesting varying therapeutic benefits by tumor genotype, acknowledges the small number of predictive biomarkers, and describes the limitations of traditional clinical trials in evaluating biomarker-treatment combinations. The rationale for the ProBio platform trial is logically linked to these gaps, and the paper explains how the adaptive design and prospective ctDNA profiling address prior limitations.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior research on biomarker-driven treatment effects and the need for platform trials, and clearly links this to the study's objectives.

Evidence

paraphrase[Main, paragraph 1]

“Retrospective analyses suggest that different tumor genotypes yield varying therapeutic benefits.”

paraphrase[Main, paragraph 3]

“A knowledge gap in treatment of men with mCRPC is that randomized data to support which of the two main treatment classes, that is, taxanes and ARPIs, provide superior outcomes or to guide treatment decisions are limited and restricted to selected patients with mCRPC who have a poor prognosis.”

paraphrase[Main, paragraph 2]

“In contrast to traditional trials, platform trials provide an effective means to evaluate and screen for novel biomarker–treatment combinations.”

PASSReviewer 2· 95% conf

The paper clearly establishes the scientific premise by citing prior work on the heterogeneity of mCRPC, the need for biomarker-driven trials, and the limitations of traditional two-armed trials in precision oncology.

Evidence

paraphrase[Main, paragraph 1-3]

“Retrospective analyses suggest that different tumor genotypes yield varying therapeutic benefits... traditional clinical trials have not been biomarker-driven and have not focused on prospectively investigating patient subgroups to identify patients who benefit more from a specific treatment.”

paraphrase[Main, paragraph 3-4]

“The advent of precision oncology... necessitates development of clinical trials that can accommodate this consequential multiplicative hypothesis testing scenario.”

“ProBio uses a number of design elements to maximize the information gained from each patient entering the trial in order to rapidly sieve through multiple hypotheses.”

Main, paragraph 4-5Find in source

Randomization is stratified on 16 biomarker subgroup combinations with adaptive probabilities. Physicians are blinded to biomarker results. Inclusion/exclusion criteria are described, including a protocol amendment limiting enrollment to first-line mCRPC. A power analysis was performed via simulation studies, with type I error <10% and power 65-83%. The primary endpoint (time to NLCB) and secondary endpoints are defined. Outlier handling is not explicitly discussed but the analysis uses a Bayesian model with vague priors, which is robust. Controls are the physician's choice arm. Replicate distinction and independent replication are not applicable for this human RCT.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingINADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The trial design is rigorous with clear randomization, stratification, adaptive randomization, and prespecified stopping rules, though blinding is limited to physicians being blinded to biomarker results (open-label treatment).

Evidence

“Randomization was stratified on these subgroups, leading to varying randomization probabilities across different subgroup levels.”

MethodsFind in source

paraphrase[Methods, Statistical analysis]

“These thresholds were calibrated through simulation studies to control type I error and ensure sufficient power.”

“Participating physicians, both in the control and investigational treatment arms, are blinded to the biomarker results.”

MethodsFind in source

PASSReviewer 2· 90% conf

The study design is well-described for a human RCT: randomization is stratified by biomarker subgroups, blinding of physicians to biomarker results is stated, inclusion/exclusion criteria are defined, and a power analysis via simulation is reported. Replicate distinction and independent replication are not applicable for this human trial.

Evidence

“Randomization was stratified on these subgroups, leading to varying randomization probabilities across different subgroup levels.”

MethodsFind in source

“Participating physicians, both in the control and investigational treatment arms, are blinded to the biomarker results.”

MethodsFind in source

paraphrase[Methods, Statistical analysis]

“These thresholds were calibrated through simulation studies to control type I error and ensure sufficient power. The estimated type I error rate was less than 10% for each therapy... Power ranged between 65% and 83% depending on the simulation scenario.”

The study includes only male patients (sex is reported). Age is reported as median and IQR in Table 1. Health status is captured by ECOG performance status. Demographics include age, ECOG, PSA levels, and prior treatments. Race/ethnicity is not reported, which is noted as a limitation in the Discussion. Species/strain and housing conditions are not applicable for a human trial.

Sub-criteria

demographicsINADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables are well reported for a human trial: sex (all male), age, ECOG status, and detailed demographics are provided; species/strain and housing are not applicable.

Evidence

“Age at study entry (median, range), years | 71 (68, 76) | 71 (65, 75) | 69 (64, 73) | 71 (68, 75) | 69 (66, 73) | 68 (66, 72)”

Table 1Find in source

paraphrase[Discussion, paragraph 5]

“Secondly, the absence of data on race and ethnicity may impact the generalizability of our findings, as these factors can affect treatment outcomes.”

PASSReviewer 2· 95% conf

Biological variables are well-reported for this human trial: sex (all male), age, ECOG status, PSA levels, ctDNA fraction, and prior treatment history are provided in Table 1. Demographics include age and comorbidities (ECOG). Species/strain and housing conditions are not applicable.

Evidence

paraphrase[Table 1]

“Age at study entry (median, range), years: 71 (68, 76)... (all patients are male by context)”

paraphrase[Table 1]

“ECOG status score of 0 or 1 at study entry, no. (%): 59 (92%)”

“the absence of data on race and ethnicity may impact the generalizability of our findings”

DiscussionFind in source

The paper states approval by ethics boards in Sweden, Belgium, Norway, and Switzerland with specific IDs. Written informed consent is mentioned. Regulatory compliance is implied through adherence to local guidelines and the Declaration of Helsinki (not explicitly named but implied).

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals are clearly documented with named ethics boards and protocol numbers, and informed consent is described.

Evidence

“approved by ethics boards in Sweden (ID: 2018/2206–32; 22 October 2018), Belgium (ID: BC-06057; 20 March 2020), Norway (ID: Søknadsnummer 81005/58005; 24 June 2020) and Switzerland (ID: BASEC 2021–02495; 01 March 2022)”

MethodsFind in source

“At inclusion and upon receiving the patient’s written informed consent, the patient is enrolled in the electronic case report form system”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approvals are adequately reported: named ethics boards in Sweden, Belgium, Norway, and Switzerland approved the study with protocol IDs. Written informed consent was obtained. Regulatory compliance with the Declaration of Helsinki is implied but not explicitly stated; however, the named approvals and consent suffice.

Evidence

MethodsFind in source

“At inclusion and upon receiving the patient’s written informed consent, the patient is enrolled in the electronic case report form system”

MethodsFind in source

The investigational products are identified: abiraterone acetate (1000 mg daily), enzalutamide (160 mg daily), docetaxel (75 mg/m2), cabazitaxel (20-25 mg/m2). The software used for analysis is R version 4.2.2, and the electronic case report form system is SMART-TRIAL. Antibodies, cell lines, mycoplasma testing, and organisms are not applicable for this human drug trial.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational products (ARPI and taxane drugs) are identified with doses and regimens, and the statistical software is identified; other bench resources are not applicable.

Evidence

“ARPIs (either 1,000 mg of abiraterone acetate or 160 mg of enzalutamide daily), taxanes (either docetaxel at a dosage of 75 mg or cabazitaxel at a dosage of 20–25 mg per square meter of body-surface area intravenously every 3 weeks)”

MethodsFind in source

“All analyses were performed in R (version 4.2.2)”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

Key resources are adequately identified for this drug trial: the investigational products (abiraterone acetate, enzalutamide, docetaxel, cabazitaxel) are named with doses and regimens. Software (R version 4.2.2, SMART-TRIAL) is identified. Antibodies, cell lines, and mycoplasma testing are not applicable.

Evidence

MethodsFind in source

“All analyses were performed in R (version 4.2.2)”

Statistical analysisFind in source

The primary analysis uses a Bayesian Weibull accelerated failure time model, with STRs and 90% CrI reported. Effect sizes are reported with credible intervals. Software (R 4.2.2) is identified. Data presentation includes Kaplan-Meier curves, posterior survival curves, and per-group Ns in tables. Exact p-values are not applicable as the analysis is Bayesian (posterior probabilities of superiority are reported). Assumptions of the Weibull model are not explicitly verified, but this is standard for such models. Mathematical plausibility checks are not applicable due to the Bayesian framework and continuous outcomes.

Sub-criteria

tests namedADEQUATE

exact p valuesN/A

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedINADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

Statistical methods are appropriate and well-described, with Bayesian Weibull models, STRs with credible intervals, and sensitivity analyses; p-values are not the primary reporting idiom.

Evidence

“We utilized a Bayesian Weibull accelerated failure time model estimated on all data (that is, first and second randomization) for the time to NLCB and on first randomization data for overall survival.”

Statistical analysisFind in source

“The STR for the time to NLCB for ARPIs was 1.50 (90% credible intervals (CrI) 1.20, 1.86)”

ResultsFind in source

PASSReviewer 2· 90% conf

Statistical analysis is rigorous: the primary analysis uses a Bayesian Weibull accelerated failure time model with STRs and 90% CrI. Tests are named, effect sizes with credible intervals are reported, software is identified, and data presentation includes Kaplan-Meier curves and per-group Ns. Exact p-values are not applicable as the analysis is Bayesian. Assumptions are not explicitly verified but the model is standard.

Evidence

“We utilized a Bayesian Weibull accelerated failure time model estimated on all data (that is, first and second randomization) for the time to NLCB”

Statistical analysisFind in source

“The STR for the time to NLCB for ARPIs was 1.50 (90% credible intervals (CrI) 1.20, 1.86)”

ResultsFind in source

“All analyses were performed in R (version 4.2.2)”

Statistical analysisFind in source

The data availability statement explains that individual patient data cannot be deposited publicly due to Swedish law, but provides a concrete access route via the corresponding author with conditions and a timeframe. Code for statistical analysis is available on GitHub.

Sub-criteria

code sharingADEQUATE

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability is clearly described with a managed-access procedure, and code is shared on GitHub.

Evidence

“Requests will be processed within 1–2 months upon submission of a complete and compliant auxiliary research-specific study protocol.”

Data availabilityFind in source

“Code for the statistical analysis is available via GitHub at https://github.com/alecri/arpi_all/”

Data availabilityFind in source

PASSReviewer 2· 90% conf

Data availability is adequately described: a data availability statement is present with a concrete access route (direct requests to the corresponding author, with conditions and timeframe). Code is shared via GitHub. Repository deposit and accession numbers are not applicable due to patient privacy restrictions.

Evidence

paraphrase[Data availability]

“Requests for data access should be directed to the corresponding author. Access to the sequencing data requires approval from the Swedish Ethical Review Authority... Requests will be processed within 1–2 months upon submission of a complete and compliant auxiliary research-specific study protocol.”

“Code for the statistical analysis is available via GitHub at https://github.com/alecri/arpi_all/”

Data availabilityFind in source

The trial is registered (NCT03903835). The primary and secondary endpoints are reported, and additional planned endpoints (QoL, cost-effectiveness) are noted as not reported here. Limitations are extensively discussed. Conclusions are proportional to the evidence. Funding sources and competing interests are declared.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedINADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper is transparent: registered, reports all prespecified outcomes, discusses limitations, and provides funding and COI statements.

Evidence

“ClinicalTrials.gov registration: NCT03903835”

AbstractFind in source

“Some limitations need to be considered when interpreting our results.”

Discussion ¶5Find in source

“The ProBio consortium thanks the following funding organizations for the following awarded research grants: ALF Medicine (to H.G., 20190087), Swedish Cancer Society (to H.G., 211610P), Swedish Research Council (to H.G., 2021-00331), Krebsliga beider Basel (to A.M., KLbB-5580-02-2022) and Kom Op Tegen Kanker/Stand up to Cancer – Flemish Cancer Society (to P.O., STI.VLK.2020.0006.01; to B.D.L., STI.VLK.2022.0005.01).”

FundingFind in source

PASSReviewer 2· 90% conf

Reporting transparency is good: the trial is registered (NCT03903835), methods are detailed, limitations are discussed, conclusions are proportional, and funding/COI are disclosed. A reporting guideline (CONSORT-like) is not explicitly referenced but the paper follows standard reporting. All pre-specified outcomes are reported.

Evidence

“ClinicalTrials.gov registration: NCT03903835 (https://clinicaltrials.gov/study/NCT03903835)”

AbstractFind in source

“Some limitations need to be considered when interpreting our results. Firstly, the chosen endpoint of NLCB as the termination point for treatment may lead to bias in open-label trials.”

DiscussionFind in source

paraphrase[Acknowledgements and Competing interests]

“The ProBio consortium thanks the following funding organizations... Competing interests... The following authors declare having received honoraria...”

Registered (1 ID: ClinicalTrials.gov). Reporting guidelines cited: CONSORT, SPIRIT.

Broken references and links

1 finding · worst low

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

Checked 55 references by DOI: 46 verified — 8 DOI unresolved, 1 no DOI (shown, not verified).

4 data/code links checked; 4 live.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly typo, consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and well-reported; an informed reader should weigh the minor reporting gaps (no explicit CONSORT statement, missing race/ethnicity data, unverified model assumptions) and the retrospective registration as transparency issues, but none warrant an erratum or independent re-analysis. The copyedit issues are trivial typos and clarity improvements.

1.
HIGHreporting
Add an explicit statement referencing the CONSORT reporting guideline in the Methods or a reporting summary section.
The paper does not explicitly reference a reporting guideline, which is a standard expectation for clinical trials and improves transparency.
2.
HIGHethics
Add a statement confirming compliance with the Declaration of Helsinki in the Methods/ethics section.
Regulatory compliance is implied but not explicitly stated; making it explicit strengthens the ethics documentation.
3.
HIGHstatistics
Explicitly verify and report assumptions of the Weibull accelerated failure time model (e.g., proportional hazards) or note that they were checked.
Reviewer 2 flagged that model assumptions are not explicitly verified; documenting this adds rigor to the statistical analysis.
4.
MEDIUMreporting
Clarify in the Discussion that additional planned secondary endpoints (QoL, cost-effectiveness) will be reported in future publications.
Reviewer 1 noted ambiguity about unreported endpoints; a clear statement avoids the impression of selective reporting.
5.
MEDIUMreporting
Include race/ethnicity data in Table 1 or discuss the limitation more prominently in the Discussion.
Missing race/ethnicity data affects generalizability; both reviewers flagged this as a limitation.
6.
MEDIUMstatistics
Provide a more detailed description of outlier handling or note that the Bayesian model is robust to outliers.
Reviewer 2 rated outlier handling as inadequate; clarifying this addresses a methodological concern.
7.
MEDIUMreporting
Clarify the direction of potential bias in the Discussion sentence about NLCB endpoint and PSA-only progressive disease.
The copyedit flagged this sentence as unclear; clarifying improves reader understanding.
8.
MEDIUMreporting
Clarify in Table 2 footnote that PPS is the probability that STR > 1.
The copyedit noted this clarity issue; a precise definition aids interpretation.
9.
LOWcopyedit
Fix the typo 'permament' to 'permanent' in Table 3 header.
Copyedit flagged this typo; correcting it improves professionalism.
10.
LOWcopyedit
Consider using exact STR values instead of approximate percentage in the Abstract for consistency with results.
Copyedit noted the approximate percentage may be less precise; using exact values improves consistency.
11.
LOWdata code
Consider depositing de-identified aggregate data in a public repository if permitted by ethical approvals.
Reviewer 2 suggested this to enhance data availability; while current managed access is adequate, public deposit would increase transparency.
12.
LOWother
Add a note on the statistical software version for the Bayesian analysis (e.g., R package used).
Reviewer 1 suggested this to improve reproducibility; specifying the package version aids replication.

Full text (77,150 chars · analyzed ~97%, head + tail)Analyzed: Aug 16, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.

Read full text (PMC)

DOI

10.1038/s41591-024-03204-2

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/4d627ac3-2234-4f07-8f7e-5ca9b6148f7f" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/4d627ac3-2234-4f07-8f7e-5ca9b6148f7f/badge" alt="Kaimen Rigor review — 3★ (Adequate), 0 critical, 3 high issues for “Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

119b0cdd1eb1faaf6a732f1d055e849abac2ab47e6cec9e5b3ab711449bddee4

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

CitationsCitations & links (capped) ×8−1★
IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★

Citations & links are capped at −1★ combined, however many are flagged.

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No reported statistical tests were found to recompute.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is time to no longer clinically benefitting (NLCB), a composite of PSA, radiologic, and clinical progression, which is a surrogate for overall survival. The paper does not provide evidence of target engagement at the tested doses (e.g., PK/PD) nor does it cite validated evidence linking NLCB to overall survival in this setting. Although overall survival is reported as a secondary endpoint, the primary efficacy claim is based on NLCB.
“The primary endpoint was the time to no longer clinically benefitting (NLCB).”
Find in source
02Other integrity concern
mediumAuthenticityreviewer-assessedFull detail
Trial NCT03903835 was first submitted to ClinicalTrials.gov on 2019-03-29, after the registered study start date of 2019-02-01. Retrospective registration means the protocol and outcomes were not on the public record before the study ran, which is what prospective registration exists to establish.
NCT03903835
reviewer’s wording

Findings by category

01ArithmeticNone found 202OverreachOverstated conclusions 103AuthenticityData authenticity concerns 04DisclosureNone found 105AvailabilityBroken references and links 06Copyedit5 minor suggestions

Numerical inconsistencies

None found

Checked — nothing surfaced.

Overstated conclusions

2 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Conclusions only partially backed by the presented evidenceAssessed

8 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Data authenticity concerns

1 finding · worst medium

Other integrity concernAssessed

1 integrity concern flagged (0 high).

Reporting gaps

None found

Checked — nothing surfaced.

Eight Dimensions8 pass

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior research on biomarker-driven treatment effects and the need for platform trials, and clearly links this to the study's objectives.

Evidence

paraphrase[Main, paragraph 1]

“Retrospective analyses suggest that different tumor genotypes yield varying therapeutic benefits.”

paraphrase[Main, paragraph 3]

paraphrase[Main, paragraph 2]

“In contrast to traditional trials, platform trials provide an effective means to evaluate and screen for novel biomarker–treatment combinations.”

PASSReviewer 2· 95% conf

Evidence

paraphrase[Main, paragraph 1-3]

paraphrase[Main, paragraph 3-4]

“The advent of precision oncology... necessitates development of clinical trials that can accommodate this consequential multiplicative hypothesis testing scenario.”

“ProBio uses a number of design elements to maximize the information gained from each patient entering the trial in order to rapidly sieve through multiple hypotheses.”

Main, paragraph 4-5Find in source

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingINADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Evidence

“Randomization was stratified on these subgroups, leading to varying randomization probabilities across different subgroup levels.”

MethodsFind in source

paraphrase[Methods, Statistical analysis]

“These thresholds were calibrated through simulation studies to control type I error and ensure sufficient power.”

“Participating physicians, both in the control and investigational treatment arms, are blinded to the biomarker results.”

MethodsFind in source

PASSReviewer 2· 90% conf

Evidence

“Randomization was stratified on these subgroups, leading to varying randomization probabilities across different subgroup levels.”

MethodsFind in source

“Participating physicians, both in the control and investigational treatment arms, are blinded to the biomarker results.”

MethodsFind in source

paraphrase[Methods, Statistical analysis]

Sub-criteria

demographicsINADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables are well reported for a human trial: sex (all male), age, ECOG status, and detailed demographics are provided; species/strain and housing are not applicable.

Evidence

“Age at study entry (median, range), years | 71 (68, 76) | 71 (65, 75) | 69 (64, 73) | 71 (68, 75) | 69 (66, 73) | 68 (66, 72)”

Table 1Find in source

paraphrase[Discussion, paragraph 5]

“Secondly, the absence of data on race and ethnicity may impact the generalizability of our findings, as these factors can affect treatment outcomes.”

PASSReviewer 2· 95% conf

Evidence

paraphrase[Table 1]

“Age at study entry (median, range), years: 71 (68, 76)... (all patients are male by context)”

paraphrase[Table 1]

“ECOG status score of 0 or 1 at study entry, no. (%): 59 (92%)”

“the absence of data on race and ethnicity may impact the generalizability of our findings”

DiscussionFind in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals are clearly documented with named ethics boards and protocol numbers, and informed consent is described.

Evidence

MethodsFind in source

“At inclusion and upon receiving the patient’s written informed consent, the patient is enrolled in the electronic case report form system”

MethodsFind in source

PASSReviewer 2· 95% conf

Evidence

MethodsFind in source

“At inclusion and upon receiving the patient’s written informed consent, the patient is enrolled in the electronic case report form system”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational products (ARPI and taxane drugs) are identified with doses and regimens, and the statistical software is identified; other bench resources are not applicable.

Evidence

MethodsFind in source

“All analyses were performed in R (version 4.2.2)”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

Evidence

MethodsFind in source

“All analyses were performed in R (version 4.2.2)”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesN/A

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedINADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

Statistical methods are appropriate and well-described, with Bayesian Weibull models, STRs with credible intervals, and sensitivity analyses; p-values are not the primary reporting idiom.

Evidence

Statistical analysisFind in source

“The STR for the time to NLCB for ARPIs was 1.50 (90% credible intervals (CrI) 1.20, 1.86)”

ResultsFind in source

PASSReviewer 2· 90% conf

Evidence

“We utilized a Bayesian Weibull accelerated failure time model estimated on all data (that is, first and second randomization) for the time to NLCB”

Statistical analysisFind in source

“The STR for the time to NLCB for ARPIs was 1.50 (90% credible intervals (CrI) 1.20, 1.86)”

ResultsFind in source

“All analyses were performed in R (version 4.2.2)”

Statistical analysisFind in source

Sub-criteria

code sharingADEQUATE

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability is clearly described with a managed-access procedure, and code is shared on GitHub.

Evidence

“Requests will be processed within 1–2 months upon submission of a complete and compliant auxiliary research-specific study protocol.”

Data availabilityFind in source

“Code for the statistical analysis is available via GitHub at https://github.com/alecri/arpi_all/”

Data availabilityFind in source

PASSReviewer 2· 90% conf

Evidence

paraphrase[Data availability]

“Code for the statistical analysis is available via GitHub at https://github.com/alecri/arpi_all/”

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedINADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper is transparent: registered, reports all prespecified outcomes, discusses limitations, and provides funding and COI statements.

Evidence

“ClinicalTrials.gov registration: NCT03903835”

AbstractFind in source

“Some limitations need to be considered when interpreting our results.”

Discussion ¶5Find in source

FundingFind in source

PASSReviewer 2· 90% conf

Evidence

“ClinicalTrials.gov registration: NCT03903835 (https://clinicaltrials.gov/study/NCT03903835)”

AbstractFind in source

“Some limitations need to be considered when interpreting our results. Firstly, the chosen endpoint of NLCB as the termination point for treatment may lead to bias in open-label trials.”

DiscussionFind in source

paraphrase[Acknowledgements and Competing interests]

“The ProBio consortium thanks the following funding organizations... Competing interests... The following authors declare having received honoraria...”

Registered (1 ID: ClinicalTrials.gov). Reporting guidelines cited: CONSORT, SPIRIT.

Broken references and links

1 finding · worst low

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

Checked 55 references by DOI: 46 verified — 8 DOI unresolved, 1 no DOI (shown, not verified).

4 data/code links checked; 4 live.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly typo, consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHreporting
Add an explicit statement referencing the CONSORT reporting guideline in the Methods or a reporting summary section.
The paper does not explicitly reference a reporting guideline, which is a standard expectation for clinical trials and improves transparency.
2.
HIGHethics
Add a statement confirming compliance with the Declaration of Helsinki in the Methods/ethics section.
Regulatory compliance is implied but not explicitly stated; making it explicit strengthens the ethics documentation.
3.
HIGHstatistics
Explicitly verify and report assumptions of the Weibull accelerated failure time model (e.g., proportional hazards) or note that they were checked.
Reviewer 2 flagged that model assumptions are not explicitly verified; documenting this adds rigor to the statistical analysis.
4.
MEDIUMreporting
Clarify in the Discussion that additional planned secondary endpoints (QoL, cost-effectiveness) will be reported in future publications.
Reviewer 1 noted ambiguity about unreported endpoints; a clear statement avoids the impression of selective reporting.
5.
MEDIUMreporting
Include race/ethnicity data in Table 1 or discuss the limitation more prominently in the Discussion.
Missing race/ethnicity data affects generalizability; both reviewers flagged this as a limitation.
6.
MEDIUMstatistics
Provide a more detailed description of outlier handling or note that the Bayesian model is robust to outliers.
Reviewer 2 rated outlier handling as inadequate; clarifying this addresses a methodological concern.
7.
MEDIUMreporting
Clarify the direction of potential bias in the Discussion sentence about NLCB endpoint and PSA-only progressive disease.
The copyedit flagged this sentence as unclear; clarifying improves reader understanding.
8.
MEDIUMreporting
Clarify in Table 2 footnote that PPS is the probability that STR > 1.
The copyedit noted this clarity issue; a precise definition aids interpretation.
9.
LOWcopyedit
Fix the typo 'permament' to 'permanent' in Table 3 header.
Copyedit flagged this typo; correcting it improves professionalism.
10.
LOWcopyedit
Consider using exact STR values instead of approximate percentage in the Abstract for consistency with results.
Copyedit noted the approximate percentage may be less precise; using exact values improves consistency.
11.
LOWdata code
Consider depositing de-identified aggregate data in a public repository if permitted by ethical approvals.
Reviewer 2 suggested this to enhance data availability; while current managed access is adequate, public deposit would increase transparency.
12.
LOWother
Add a note on the statistical software version for the Bayesian analysis (e.g., R package used).
Reviewer 1 suggested this to improve reproducibility; specifying the package version aids replication.

Full text (77,150 chars · analyzed ~97%, head + tail)Analyzed: Aug 16, 2026